Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/10977
Title: A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study.
Authors: Proietto, Joseph;Rissanen, A;Harp, J B;Erondu, N;Yu, Q;Suryawanshi, S;Jones, Mark E;Johnson-Levonas, A O;Heymsfield, S B;Kaufman, K D;Amatruda, J M
Affiliation: Department of Medicine, University of Melbourne, Heidelberg Repatriation Hospital, Melbourne, Victoria, Australia. j.proietto@unimelb.edu.au
Issue Date: 9-Mar-2010
Citation: International Journal of Obesity (2005) 2010; 34(8): 1243-54
Abstract: To evaluate the weight loss efficacy, safety and tolerability of taranabant, a CB1R inverse agonist, in obese and overweight patients.Multicenter, double-blind, randomized, placebo-controlled study.Patients >or=18 years old, BMI 27-43 kg m(-2), were randomized to placebo (n=209) or taranabant 0.5 mg (n=207), 1 mg (n=208) or 2 mg given orally once daily (n=417) for 52 weeks.Key efficacy measurements included body weight (BW), waist circumference (WC), lipid endpoints and glycemic endpoints.Based on a last observation carried forward analysis of the all-patients-treated population, mean change in BW for taranabant 0.5, 1, and 2 mg and placebo was -5.4, -5.3, -6.7 and -1.7 kg, respectively (P<0.001 for all doses vs placebo). The proportions of patients who lost at least 5 and 10% of their baseline BW at week 52 were significantly higher for all taranabant doses vs placebo (P<0.001 for all doses). Reductions in WC, percentage of body fat, and triglycerides were significant for taranabant 2 mg and in triglycerides for taranabant 1 mg vs placebo. There was no effect of taranabant vs placebo on other lipid or glucose-related endpoints. Incidences of adverse experiences classified in the gastrointestinal (diarrhea and nausea), nervous system (dizziness/dizziness postural), psychiatric-related (irritability and anger/aggression) and vascular (flushing/hot flush) organ systems were higher and statistically significant in the taranabant 2-mg group compared with the placebo group. Irritability was higher and statistically significant in all taranabant groups compared with the placebo group.All three doses of taranabant-induced clinically meaningful and statistically significant weight loss. Incidences of adverse experiences in organ systems known to express CB1R were higher in taranabant groups.
Internal ID Number: 20212496
URI: http://ahro.austin.org.au/austinjspui/handle/1/10977
DOI: 10.1038/ijo.2010.38
URL: http://www.ncbi.nlm.nih.gov/pubmed/20212496
Type: Journal Article
Subjects: Administration, Oral
Adult
Aged
Aged, 80 and over
Amides.administration & dosage
Anti-Obesity Agents.administration & dosage
Body Weight.drug effects
Dose-Response Relationship, Drug
Double-Blind Method
Female
Humans
Male
Middle Aged
Obesity.drug therapy
Pyridines.administration & dosage
Questionnaires
Receptor, Cannabinoid, CB1.antagonists & inhibitors
Weight Loss
Young Adult
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.